AtriCure (ATRC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.18
- EPS estimate
- −$0.00
- EPS surprise
- +10688.24%
- Revenue surprise
- +1.19%
- Revenue
- $153.6M
- Revenue estimate
- $151.8M
- Reported
- Jul 23, 2026
AtriCure reported Q2 2026 results on July 23, 2026. Earnings per share were $0.18, against an estimate of roughly zero, so the source's surprise figure is not meaningful. Revenue was $153.6 million against a $151.8 million estimate, the highest in the table. A year earlier, Q2 2025 was a loss of $0.13 per share, and revenue has since risen about 13% from $136.1 million.
Annual revenue rose from $330.3 million in 2022 to $534.5 million in 2025, about 62% higher. Annual losses were $1.01 per share in 2022, $0.66 in 2023, $0.95 in 2024 and $0.24 in 2025. Every quarter from Q4 2021 to Q3 2025 was a loss. Since then, EPS has been $0.04 in Q4 2025, $0.00 in Q1 2026 and $0.18 in Q2 2026. The earliest row, Q3 2021, shows an unusually large profit of $2.11 per share, unlike the rest of the table. AtriCure beat EPS estimates in 13 of the last 20 quarters, including the last 4.
AtriCure reported Q3 between October 29 and November 3 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether EPS stays positive.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | −$0.00 | $0.18 | +10688.24% | $153.6M | SEC |
| Q1 2026 | May 5, 2026 | −$0.06 | $0.00 | +100.00% | $141.2M | SEC |
| Q4 2025 | Feb 17, 2026 | −$0.09 | $0.04 | +146.08% | $140.5M | SEC |
| Q3 2025 | Oct 29, 2025 | −$0.11 | −$0.01 | +91.06% | $134.3M | SEC |
| Q2 2025 | Jul 29, 2025 | −$0.17 | −$0.13 | +22.20% | $136.1M | SEC |
| Q1 2025 | Apr 29, 2025 | −$0.23 | −$0.14 | +37.78% | $123.6M | SEC |
| Q4 2024 | Feb 12, 2025 | −$0.20 | −$0.33 | −63.12% | $124.3M | SEC |
| Q3 2024 | Oct 29, 2024 | −$0.19 | −$0.17 | +12.78% | $115.9M | SEC |
| Q2 2024 | Jul 30, 2024 | −$0.17 | −$0.17 | −1.13% | $116.3M | SEC |
| Q1 2024 | May 1, 2024 | −$0.23 | −$0.28 | −22.06% | $108.9M | SEC |
| Q4 2023 | Feb 15, 2024 | −$0.22 | −$0.21 | +6.58% | $106.5M | SEC |
| Q3 2023 | Nov 1, 2023 | −$0.30 | −$0.20 | +34.32% | $98.3M | SEC |
| Q2 2023 | Jul 25, 2023 | −$0.30 | −$0.11 | +62.86% | $100.9M | SEC |
| Q1 2023 | May 2, 2023 | −$0.31 | −$0.14 | +54.85% | $93.5M | SEC |
| Q4 2022 | Feb 21, 2023 | −$0.18 | −$0.09 | +48.89% | $88.0M | SEC |
| Q3 2022 | Nov 1, 2022 | −$0.26 | −$0.27 | −5.14% | $83.2M | SEC |
| Q2 2022 | Aug 2, 2022 | −$0.29 | −$0.32 | −9.18% | $84.5M | SEC |
| Q1 2022 | May 3, 2022 | −$0.32 | −$0.33 | −3.13% | $74.6M | SEC |
| Q4 2021 | Feb 15, 2022 | −$0.29 | −$0.30 | −3.45% | $73.2M | SEC |
| Q3 2021 | Nov 3, 2021 | −$0.33 | $2.11 | +748.03% | $70.5M | SEC |
Quarterly revenue
Frequently asked questions
When did AtriCure (ATRC) last report earnings?
AtriCure last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did ATRC beat earnings estimates?
Yes. AtriCure reported EPS of $0.18 for Q2 2026 against a −$0.00 estimate — a 10688.24% beat.
How much revenue did ATRC report last quarter?
AtriCure reported $153.6M in revenue for Q2 2026, against a consensus estimate of $151.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.